KAHR's lead drug candidate, DSP107, is a first-in-class bi-specific 4-1BB T-cell engager utilizing CD47 overexpression as a tumor anchor. DSP107 binds to CD47 that cancer cells express on their ...

For the email address or phone number above, please check the boxes of the products and services for which you no longer wish to receive offers and promotions. If you do not check the box, you will ...

2025 /PRNewswire/ -- KAHR, a clinical-stage biotech company developing DSP107, a first-in-class bi-specific 4-1BB T-cell engager that activates innate and adaptive immunity to treat solid tumors ...

The MSS-CRC dose expansion phase of the study was an open label, multi-center trial (NCT04440735) that enrolled patients with 3rd line MSS colorectal cancer patients, treated weekly with 10 mg/kg ...

DSP107 in combination with atezolizumab in 3 rd line microsatellite stable colorectal cancer (MSS-CRC) patients elicits anti-tumor activity and extends survival including in patients with liver ...

But somehow, 18 episodes of 9-1-1 Season 8 have come and gone. So now fans are left to wonder what’s in store for the future of ABC’s hit first responder drama… 9-1-1 wrapped its most ...